EUVIMEDEUVIMED entdecken
Netzwerk-MetaanalyseVergleichsstudie

Comparative Cardiorenal Efficacy and Safety of Finerenone, SGLT2 Inhibitors, Semaglutide and Their Combination in Diabetic Kidney Disease

Ziyan Zhou, Linghua Fu, Dan Chen, Peng Yu, Gaosi Xu iD, Qinghua Wu, Tao Wu, Pingping Yang iD

Diabetes, Obesity and Metabolism · 2026-12 · 28 (12) · 11440-11451

DOI: 10.1111/dom.71305 ↗

Kurz gefasst

Netzwerk-Metaanalyse in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 17.09.2026. Verfasst von Ziyan Zhou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetic Nephropathies, Diabetes Mellitus, Type 2, Glucagon-Like Peptides. Die Arbeit nennt 44 Literaturangaben. Gefördert von: Jiangxi Provincial Natural Science Foundation, The Youth Fund of the National Natural Science Foundation of Jiangxi Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To compare the cardiorenal efficacy and safety of finerenone, sodium–glucose cotransporter 2 inhibitors (SGLT2i), semaglutide and finerenone–SGLT2i combination therapy in diabetic kidney disease (DKD). Materials and Methods PubMed, Embase and CENTRAL were searched through July 9, 2026 for randomized trials involving adults with Type 2 diabetes and DKD. A frequentist network meta‐analysis estimated risk ratios (RRs) with 95% confidence intervals (CIs) for cardiorenal and safety outcomes.

Results

Ten randomized datasets involving 37 923 participants were included. Compared with control, dapagliflozin, canagliflozin, finerenone and semaglutide reduced both cardiovascular composite events and composite kidney outcomes; sotagliflozin reduced cardiovascular composite events, and empagliflozin reduced composite kidney outcomes. SGLT2i showed the broadest overall pattern of benefit across cardiorenal outcomes. Dapagliflozin was associated with a lower risk of the composite kidney outcome than semaglutide (RR 0.71, 95% CI: 0.53–0.94), while most other efficacy comparisons between active monotherapies were not statistically significant. Finerenone increased hyperkalaemia (RR 2.03, 95% CI: 1.82–2.26) and treatment discontinuation due to adverse events (RR 1.18, 95% CI: 1.02–1.35). Finerenone plus empagliflozin was associated with a higher risk of hyperkalaemia than empagliflozin alone (RR 2.48, 95% CI: 1.22–5.06).

Conclusions

SGLT2i showed the broadest cardiorenal benefits, while finerenone and semaglutide provided additional protection across selected outcomes. Finerenone increased hyperkalaemia and treatment discontinuation. The efficacy of finerenone–SGLT2i combination therapy requires further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsDiabetic NephropathiesDiabetes Mellitus, Type 2Glucagon-Like PeptidesNaphthyridinesHumansSemaglutideDrug Therapy, CombinationBenzhydryl CompoundsHypoglycemic AgentsGlucosidesRandomized Controlled Trials as TopicTreatment Outcome

Stichwörter der Autor:innen

combination therapydiabetic kidney diseasefinerenonesemaglutidesodium–glucose cotransporter 2 inhibitors

Substanzen

SemaglutideSodium-Glucose Transporter 2 InhibitorsGlucagon-Like PeptidesfinerenoneNaphthyridinesBenzhydryl CompoundsHypoglycemic AgentsGlucosidesempagliflozindapagliflozin

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
  • Department of Geriatrics, General Hospital of Central Theater Command, Wuhan, China.
  • Department of Endocrinology and Metabolism, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
  • Department of Nephrology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.

ORCID-Profile: Gaosi Xu, Pingping Yang

Förderung

  • Jiangxi Provincial Natural Science Foundation
  • The Youth Fund of the National Natural Science Foundation of Jiangxi Province
  • National Natural Science Foundation of China
  • The "Ganpo Talents Support Program" of Jiangxi Province under the "Health Outstanding Talents (Cultivation)" project
  • Natural Science Foundation of Jiangxi Province

Zitieren

APA

Zhou, Z., Fu, L., Chen, D., Yu, P., Xu, G., Wu, Q., Wu, T., & Yang, P. (2026). Comparative Cardiorenal Efficacy and Safety of Finerenone, SGLT2 Inhibitors, Semaglutide and Their Combination in Diabetic Kidney Disease. Diabetes, Obesity and Metabolism, 28(12), 11440-11451. https://doi.org/10.1111/dom.71305

Vancouver

Zhou Z, Fu L, Chen D, Yu P, Xu G, Wu Q, et al. Comparative Cardiorenal Efficacy and Safety of Finerenone, SGLT2 Inhibitors, Semaglutide and Their Combination in Diabetic Kidney Disease. Diabetes, Obesity and Metabolism. 2026;28(12):11440-11451. doi:10.1111/dom.71305

BibTeX
@article{Zhou2026,
  author = {Zhou, Ziyan and Fu, Linghua and Chen, Dan and Yu, Peng and Xu, Gaosi and Wu, Qinghua and Wu, Tao and Yang, Pingping},
  title = {Comparative Cardiorenal Efficacy and Safety of Finerenone, SGLT2 Inhibitors, Semaglutide and Their Combination in Diabetic Kidney Disease},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {12},
  pages = {11440--11451},
  doi = {10.1111/dom.71305}
}
Kostenlos starten →